keyword
MENU ▼
Read by QxMD icon Read
search

Marijuana and Parkinsons

keyword
https://www.readbyqxmd.com/read/28571738/gpr3-and-gpr6-novel-molecular-targets-for-cannabidiol
#1
Alyssa S Laun, Zhao-Hui Song
GPR3 and GPR6 are members of a family of constitutively active, Gs protein-coupled receptors. Previously, it has been reported that GPR3 is involved in Alzheimer's disease whereas GPR6 plays potential roles in Parkinson's disease. GPR3 and GPR6 are considered orphan receptors because there are no confirmed endogenous agonists for them. However, GPR3 and GPR6 are phylogenetically related to the cannabinoid receptors. In this study, the activities of endocannabinoids and phytocannabinoids were tested on GPR3 and GPR6 using a β-arrestin2 recruitment assay...
May 29, 2017: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/28370445/media-hype-patient-and-scientific-perspectives-on-misleading-medical-news
#2
Israel Robledo, Joseph Jankovic
In this age of digital technology, Internet, and social media we are increasingly subjected to an information and disinformation overload. This includes not only political and economic information but also medical news, which is often presented as a "new discovery", "miracle cure" or some other press hyperbole. In this viewpoint article we present patient and scientific perspectives some recent episodes of medical hype related to Parkinson's disease research, including proposed therapies such as nilotinib, marijuana, stem cells and other controversial therapies that have attracted the mainstream and social media...
April 3, 2017: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/28266899/the-blue-lotus-flower-nymphea-caerulea-resin-used-in-a-new-type-of-electronic-cigarette-the-re-buildable-dripping-atomizer
#3
Justin L Poklis, Haley A Mulder, Matthew S Halquist, Carl E Wolf, Alphonse Poklis, Michelle R Peace
The blue lotus flower (Nymphea caerulea) is an Egyptian water lily containing apomorphine and nuciferine. Apomorphine has been described as a psychoactive alkaloid and is a non-selective dopamine agonist primarily used to treat Parkinson's disease as it stimulates dopamine receptors and improves motor function. Nuciferine is an alkaloid associated with dopamine receptor blockade. Today, blue lotus flower is used as a sleep aid and anxiety reliever. The rebuildable dripping atomizer (RDA) is an electronic cigarette that allows direct application of an e-liquid onto the coil in the atomizer for aerosolization, compared to a typical electronic cigarette where the e-liquid is wicked from a storage vessel to the coil...
March 7, 2017: Journal of Psychoactive Drugs
https://www.readbyqxmd.com/read/27789118/adverse-structural-and-functional-effects-of-marijuana-on-the-brain-evidence-reviewed
#4
REVIEW
David E Mandelbaum, Suzanne M de la Monte
The growing use and legalization of cannabis are leading to increased exposures across all age groups, including in adolescence. The touting of its medicinal values stems from anecdotal reports related to treatment of a broad range of illnesses including epilepsy, multiple sclerosis, muscle spasms, arthritis, obesity, cancer, Alzheimer disease, Parkinson disease, post-traumatic stress, inflammatory bowel disease, and anxiety. However, anecdotal data and the high level of interest in this treatment must not obscure objective assessments of any potential and realized short- and long-term adverse effects of cannabis, particularly with respect to age of onset and chronicity of exposure...
January 2017: Pediatric Neurology
https://www.readbyqxmd.com/read/27086601/endocannabinoid-system-a-multi-facet-therapeutic-target
#5
REVIEW
Rimplejeet Kaur, Sneha R Ambwani, Surjit Singh
Cannabis sativa is also popularly known as marijuana. It has been cultivated and used by man for recreational and medicinal purposes since many centuries. Study of cannabinoids was at bay for very long time and its therapeutic value could not be adequately harnessed due to its legal status as proscribed drug in most of the countries. The research of drugs acting on endocannabinoid system has seen many ups and downs in the recent past. Presently, it is known that endocannabinoids has role in pathology of many disorders and they also serve "protective role" in many medical conditions...
2016: Current Clinical Pharmacology
https://www.readbyqxmd.com/read/26926078/methamphetamine-induced-dopaminergic-toxicity-prevented-owing-to-the-neuroprotective-effects-of-salicylic-acid
#6
Bessy Thrash-Williams, Senthilkumar S Karuppagounder, Dwipayan Bhattacharya, Manuj Ahuja, Vishnu Suppiramaniam, Muralikrishnan Dhanasekaran
AIMS: Methamphetamine (Schedule-II drug, U.S. Drug Enforcement Administration) is one of the most abused illicit drug following cocaine, marijuana, and heroin in the USA. There are numerous health impairments and substantial economic burden caused by methamphetamine abuse. Salicylic acid, potent anti-inflammatory drug and a known neuroprotectant has shown to protect against toxicity-induced by other dopaminergic neurotoxins. Hence, in this study we investigated the neuroprotective effects of salicylic acid against methamphetamine-induced toxicity in mice...
June 1, 2016: Life Sciences
https://www.readbyqxmd.com/read/25649017/the-therapeutic-potential-of-cannabinoids-for-movement-disorders
#7
REVIEW
Benzi Kluger, Piera Triolo, Wallace Jones, Joseph Jankovic
There is growing interest in the therapeutic potential of marijuana (cannabis) and cannabinoid-based chemicals within the medical community and, particularly, for neurological conditions. This interest is driven both by changes in the legal status of cannabis in many areas and increasing research into the roles of endocannabinoids within the central nervous system and their potential as symptomatic and/or neuroprotective therapies. We review basic science as well as preclinical and clinical studies on the therapeutic potential of cannabinoids specifically as it relates to movement disorders...
March 2015: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/24971285/the-endocannabinoid-system-a-putative-role-in-neurodegenerative-diseases
#8
REVIEW
Giuseppe Di Iorio, Matteo Lupi, Fabiola Sarchione, Ilaria Matarazzo, Rita Santacroce, Filippo Petruccelli, Giovanni Martinotti, Massimo Di Giannantonio
BACKGROUND: Following the characterization of the chemical structure of D9-tetrahydrocannabinol (THC), the main psychoactive constituent of marijuana, researchers have moved on with scientific valuable explorations. OBJECTIVES: The aim of this review is to highlight the role of endocannabinoid system in neurodegenerative diseases. MATERIALS AND METHODS: The article is a critical analysis of the most recent data currently present in scientific literature on the subject; a qualitative synthesis of only the most significant articles has been performed...
December 2013: International Journal of High Risk Behaviors & Addiction
https://www.readbyqxmd.com/read/24778283/systematic-review-efficacy-and-safety-of-medical-marijuana-in-selected-neurologic-disorders-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology
#9
REVIEW
Barbara S Koppel, John C M Brust, Terry Fife, Jeff Bronstein, Sarah Youssof, Gary Gronseth, David Gloss
OBJECTIVE: To determine the efficacy of medical marijuana in several neurologic conditions. METHODS: We performed a systematic review of medical marijuana (1948-November 2013) to address treatment of symptoms of multiple sclerosis (MS), epilepsy, and movement disorders. We graded the studies according to the American Academy of Neurology classification scheme for therapeutic articles. RESULTS: Thirty-four studies met inclusion criteria; 8 were rated as Class I...
April 29, 2014: Neurology
https://www.readbyqxmd.com/read/24614667/cannabis-medical-marijuana-treatment-for-motor-and-non-motor-symptoms-of-parkinson-disease-an-open-label-observational-study
#10
Itay Lotan, Therese A Treves, Yaniv Roditi, Ruth Djaldetti
OBJECTIVE: The use of cannabis as a therapeutic agent for various medical conditions has been well documented. However, clinical trials in patients with Parkinson disease (PD) have yielded conflicting results. The aim of the present open-label observational study was to assess the clinical effect of cannabis on motor and non-motor symptoms of PD. METHODS: Twenty-two patients with PD attending the motor disorder clinic of a tertiary medical center in 2011 to 2012 were evaluated at baseline and 30 minutes after smoking cannabis using the following battery: Unified Parkinson Disease Rating Scale, visual analog scale, present pain intensity scale, Short-Form McGill Pain Questionnaire, as well as Medical Cannabis Survey National Drug and Alcohol Research Center Questionnaire...
March 2014: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/20632970/cannabinoid-receptors-and-endocannabinoids-role-in-neuroinflammatory-and-neurodegenerative-disorders
#11
REVIEW
Tiziana Bisogno, Vincenzo Di Marzo
The G-protein coupled receptors for Δ⁹-tetrahydrocannabinol, the major psychoactive principle of marijuana, are known as cannabinoid receptors of type 1 (CB₁) and 2 (CB₂) and play important functions in degenerative and inflammatory disorders of the central nervous system. Whilst CB₁ receptors are mostly expressed in neurons, where they regulate neurotransmitter release and synaptic strength, CB₂ receptors are found mostly in glial cells and microglia, which become activated and over-express these receptors during disorders such as Alzheimer's disease, multiple sclerosis, amyotropic lateral sclerosis, Parkinson's disease, and Huntington's chorea...
November 2010: CNS & Neurological Disorders Drug Targets
https://www.readbyqxmd.com/read/19356123/endocannabinoid-system-emerging-role-from-neurodevelopment-to-neurodegeneration
#12
REVIEW
Balapal S Basavarajappa, Ralph A Nixon, Ottavio Arancio
The endocannabinoid system, including endogenous ligands ('endocannabinoids' ECs), their receptors, synthesizing and degrading enzymes, as well as transporter molecules, has been detected from the earliest stages of embryonic development and throughout pre- and postnatal development. ECs are bioactive lipids, which comprise amides, esters and ethers of long chain polyunsaturated fatty acids. Anandamide (N-arachidonoylethanolamine; AEA) and 2-arachidonoylglycerol (2-AG) are the best studied ECs, and act as agonists of cannabinoid receptors...
April 2009: Mini Reviews in Medicinal Chemistry
https://www.readbyqxmd.com/read/19228180/cannabidiol-a-promising-drug-for-neurodegenerative-disorders
#13
REVIEW
Teresa Iuvone, Giuseppe Esposito, Daniele De Filippis, Caterina Scuderi, Luca Steardo
Neurodegenerative diseases represent, nowadays, one of the main causes of death in the industrialized country. They are characterized by a loss of neurons in particular regions of the nervous system. It is believed that this nerve cell loss underlies the subsequent decline in cognitive and motor function that patients experience in these diseases. A range of mutant genes and environmental toxins have been implicated in the cause of neurodegenerative disorders but the mechanism remains largely unknown. At present, inflammation, a common denominator among the diverse list of neurodegenerative diseases, has been implicated as a critical mechanism that is responsible for the progressive nature of neurodegeneration...
2009: CNS Neuroscience & Therapeutics
https://www.readbyqxmd.com/read/18286801/cannabinoids-in-health-and-disease
#14
REVIEW
Natalya M Kogan, Raphael Mechoulam
Cannabis sativa L. preparations have been used in medicine for millenia. However, concern over the dangers of abuse led to the banning of the medicinal use of marijuana in most countries in the 1930s. Only recently, marijuana and individual natural and synthetic cannabinoid receptor agonists and antagonists, as well as chemically related compounds, whose mechanism of action is still obscure, have come back to being considered of therapeutic value. However, their use is highly restricted. Despite the mild addiction to cannabis and the possible enhancement of addiction to other substances of abuse, when combined with cannabis, the therapeutic value of cannabinoids is too high to be put aside...
2007: Dialogues in Clinical Neuroscience
https://www.readbyqxmd.com/read/17274532/the-endocannabinoid-system-in-neurodegeneration
#15
REVIEW
Natalia Battista, Filomena Fezza, Alessandro Finazzi-Agrò, Mauro Maccarrone
Endocannabinoids are bioactive lipids, that comprise amides, esters and ethers of long chain polyunsaturated fatty acids. Anandamide (N-arachidonoylethanolamine; AEA) and 2-arachidonoylglycerol (2-AG) are the best studied endocannabinoids, and act as agonists of cannabinoid receptors. Thus, AEA and 2-AG mimic several pharmacological effects of the exogenous cannabinoid delta9-tetrahydrocannabinol, the psychoactive principle of hashish and marijuana. It is known that the activity of endocannabinoids at their receptors is limited by cellular uptake through specific membrane transporters, followed by intracellular degradation by a fatty acid amide hydrolase (for AEA and partly 2-AG) or by a monoacylglycerol lipase (for 2-AG)...
September 2006: Italian Journal of Biochemistry
https://www.readbyqxmd.com/read/17239356/dorsolateral-prefrontal-cortex-n-acetylaspartate-total-creatine-naa-tcr-loss-in-male-recreational-cannabis-users
#16
Derik Hermann, Alexander Sartorius, Helga Welzel, Sigrid Walter, Gisela Skopp, Gabriele Ende, Karl Mann
BACKGROUND: Cannabinoids present neurotoxic and neuroprotective properties in in vitro studies, inconsistent alterations in human neuroimaging studies, neuropsychological deficits, and an increased risk for psychotic episodes. METHODS: Proton magnetic resonance spectroscopy ((1)H-MRS), neuropsychological testing, and hair analysis for cannabinoids was performed in 13 male nontreatment-seeking recreational cannabis users and 13 male control subjects. RESULTS: A significantly diminished N-acetylaspartate/total creatine (NAA/tCr) ratio in the dorsolateral prefrontal cortex (DLPFC) was observed in cannabis users (p = ...
June 1, 2007: Biological Psychiatry
https://www.readbyqxmd.com/read/16699878/implication-of-cannabinoids-in-neurological-diseases
#17
REVIEW
Angela Alsasua del Valle
1. Preparations from Cannabis sativa (marijuana) have been used for many centuries both medicinally and recreationally. 2. Recent advances in the knowledge of its pharmacological and chemical properties in the organism, mainly due to Delta(9)-tetrahydrocannabinol, and the physiological roles played by the endocannabinoids have opened up new strategies in the treatment of neurological and psychiatric diseases. 3. Potential therapeutic uses of cannabinoid receptor agonists include the management of spasticity and tremor in multiple sclerosis/spinal cord injury, pain, inflammatory disorders, glaucoma, bronchial asthma, cancer, and vasodilation that accompanies advanced cirrhosis...
July 2006: Cellular and Molecular Neurobiology
https://www.readbyqxmd.com/read/15895873/recent-developments-in-the-therapeutic-potential-of-cannabinoids
#18
REVIEW
Susan Corey
OBJECTIVE: To examine the recent evidence that marijuana and other cannabinoids have therapeutic potential. METHODS: Literature published since 1997 was searched using the following terms: cannabinoid, marijuana, THC, analgesia, cachexia, glaucoma, movement, multiple sclerosis, neurological, pain, Parkinson, trial, vomiting. Qualifying clinical studies were randomized, double-blind, and placebo-controlled. Selected open-label studies and surveys are also discussed...
March 2005: Puerto Rico Health Sciences Journal
https://www.readbyqxmd.com/read/15372606/survey-on-cannabis-use-in-parkinson-s-disease-subjective-improvement-of-motor-symptoms
#19
Katerina Venderová, Evzen Růzicka, Viktor Vorísek, Peter Visnovský
An anonymous questionnaire sent to all patients attending the Prague Movement Disorder Centre revealed that 25% of 339 respondents had taken cannabis and 45.9% of these described some form of benefit.
September 2004: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/15247852/-cannabis-and-cannabinoid-receptors-from-pathophysiology-to-therapeutic-options
#20
REVIEW
P Derkinderen, E Valjent, F Darcel, P Damier, J-A Girault
BACKGROUND: Although cannabis has been used as a medicine for several centuries, the therapeutic properties of cannabis preparations (essentially haschich and marijuana) make them far most popular as a recreational drugs. STATE OF THE ART: Scientific studies on the effects of cannabis were advanced considerably by the identification in 1964 of cannabinoid D9-tetrahydrocannadinol (THC), recognized as the major active constituent of cannabis. Cloning of the centrally located CB1 receptor in 1990 and the identification of the first endogenous ligand of the CB1 receptor, anandamide, in 1992 further advanced our knowledge...
July 2004: Revue Neurologique
keyword
keyword
57775
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"